Upload
thomas-johns
View
219
Download
1
Tags:
Embed Size (px)
Citation preview
Methods and Early Results from AHRQ’s Healthcare Horizon Scanning System
Karen Schoelles MD, SMProject Director, AHRQ Healthcare Horizon
Scanning SystemECRI Institute
AHRQ Annual MeetingSeptember 10, 2012
AHRQ Healthcare Horizon Scanning System
Purpose: – To inform and guide the planning and
prioritization of patient-centered outcomes research investments through the Effective Health Care Program
AHRQ Healthcare Horizon Scanning System
Description: A process– to identify and monitor health care
innovations– to create an inventory of innovations that
address an unmet need and have the highest potential for impact on clinical care, the health care system, patient outcomes and costs
Why Scan the Horizon?
“Horizon scanning aims to help break the element of surprise – shifting our focus earlier along the stages of change to allow proactive planning and decision making.
Without horizon scanning, things seem to “come out of nowhere” but really they are just entering our consciousness at a late point in the stages of change.”
― Jennifer DeLurio, Horizon Scanning Leads Manager
Effective Health Care Website page for Horizon Scanning Overview
http://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=881
AHRQ Healthcare Horizon Scanning System
Range of interventions:– Drugs, biologics, medical devices– Procedures– Screening and diagnostic tests, including
imaging– Behavioral health interventions– Care delivery innovations
Includes new uses of existing/diffused interventions
AHRQ Priority Conditions1. Arthritis and nontraumatic joint disease2. Cancer3. Cardiovascular disease4. Dementia (including Alzheimer’s)5. Depression and other mental health disorders6. Developmental delays, attention-deficit hyperactivity
disorder & autism 7. Diabetes mellitus
AHRQ Priority Conditions, continued
8. Functional limitations and disability9. Infectious disease, including HIV/AIDS10.Obesity11. Peptic ulcer disease and dyspepsia12.Pregnancy, including preterm birth13.Pulmonary disease/asthma14.Substance abuse15. (Cross-cutting topics)
Stages of Horizon Scanning
Identify the users Determine the timeframe Conduct horizon scanning and identify
emerging technologies Filter the identified technologies Prioritize the technologies
Stages of Horizon Scanning, continued
Assess technologies of high priority Use peer review to check for quality Disseminate the information Update the information
AHRQ Healthcare Horizon Scanning System: Identified Users
Primarily AHRQ Other CER/PCOR funders Researchers Consumers/patients
AHRQ Horizon Scanning Timeframe
Diffusion into Medical Practice
Initial evaluations in
humans
Approval, clearance, initial
dissemination
7 years 2 years
AHRQ Healthcare Horizon Scanning and Identification of Interventions
Broad scanning and lead selection:– About 100 selected sources plus meeting
abstracts– 12 medical librarians scan these sources
regularly for leads– Leads are selected if they relate to one or
more Priority Conditions– Leads coalesce into specific topics
AHRQ Horizon Scanning: Filtering and Prioritization
Protocol defines criteria Primary question: Does it address an
unmet need?– Gap in effective ways to
Screen Diagnose Treat Monitor Manage Provide or deliver care
Assessing High Priority Topics
Analysts nominate topics based on protocol-defined criteria
Selected topics investigated with specific searches for information
Experts are asked to comment on reports
AHRQ Horizon Scanning Status Reports
Inventory of topics followed as of prior report new topics added since prior report topics archived since prior report
AHRQ Horizon Scanning Status Reports
Topic Title PotentialPatient
Population
InterventionDeveloper/Manufacturer(s)
Phase of Development
Potential Comparators
Potential Health
or Other Impacts
NS5A inhibitor (IDX-719) for treatment of chronic hepatitis C infection
Patients in whom chronic hepatitis C virus (HCV) infection has been diagnosed
Standard of care for HCV infection has a long dosing schedule and poor tolerability. Better-tolerated treatments with more convenient dosing are needed. IDX-719 is an oral NS5A inhibitor purported to block the ability of the viral NS5A protein to attach to the endoplasmic reticulum of infected hepatocytes, which is thought to be required for the formation of functional viral particles. IDX-719 purportedly inhibits the activity of all HCV genotypes and has been administered up to 50 mg, once daily. Idenix Pharmaceuticals, Inc., Cambridge, MA Phase I/II trial ongoing
BoceprevirNS5A inhibitors in development
Nonnucleoside polymerase inhibitors in development
Nucleoside polymerase inhibitors in development
Pegylated interferon/ribavirin combinationTelaprevir
Slowed or halted disease progression
Sustained virologic response (defined as undetectable virus at 24 weeks)
Decreased need for liver transplant
Improved quality of life
Horizon Scanning: Assessing Potential for Impact
Seven parameters:– Potential importance of the unmet need– Potential to improve patient health – Potential to affect health disparities– Potential to disrupt the health care delivery
system– Potential for adoption by clinicians and/or
patients– Potential impact on cost– Overall potential to meet the unmet need
Input on Potential for Impact
Approximately 350 experts nationwide Experts with a variety of perspectives:
– clinical practice– clinical research– health care delivery– health business– health technology assessment– health facility administration
Input on Potential for Impact
Each expert asked to disclose any potential intellectual or financial conflicts of interest (COI).
Perspectives of an expert with a COI are balanced by perspectives of experts without COIs.
No more than two experts with a possible COI are considered out of a total of the seven or eight experts who are sought to provide comment for each topic
Horizon Scanning: Assessing Potential for Impact
Eligible topics:– Within 0–4 years of potential diffusion (e.g.,
in phase III trials or preliminary efficacy data in the target population) in the United States
– Or in very early diffusion Comments received from at least 6 – 8
experts
Sample Potential High Impact Report: Priority Condition 9 – Infectious Diseases
June 2012 107 Infectious Disease topics tracked in the
system as of May 2012 11 topics eligible for Potential High Impact
assessment and comments received from 6 – 8 experts
9 of 11 selected as having potential for high impact based on comments received– 6 at higher end of “high”– 2 in moderately high range– 1 at lower end of “high”
Sample Topics Selected for Potential High Impact Report
Hepatitis C Virus Infection Interventions– NS3/4A Protease Inhibitors (Boceprevir and
Telaprevir) for Treatment of Chronic Hepatitis C Infection - HIGH
HIV/AIDS Interventions– Collaborative Care Model for Treatment of HIV
and Comorbid Depression – LOWER END OF HIGH
– Emtricitabine/Tenofovir (Truvada) for Prevention of HIV Infection - HIGH
– Routine Anal Pap Smear Screening at HIV Clinics to Prevent Anal Cancer – MODERATATLEY HIGH
Sample Topics Selected for Potential High Impact Report, continued
Healthcare-Acquired and Bacterial Infection Interventions– Antimicrobial Copper Surfaces in the ICU for
Prevention of Healthcare-Acquired Infections - HIGH
– Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection - HIGH
– Fidaxomicin (Dificid) for Treatment of Clostridium difficile Infection - HIGH
– Xpert MTB/RIF Test for Simultaneous Detection and Drug Sensitivity Testing of Mycobacterium Tuberculosis – MODERATELY HIGH
Topics Eligible for Assessment
*Controlled release phentermine/topiramate (Qnexa®) for treatment of obesity*EndoBarrier Endoluminal Sleeve for treatment of obesity
Full Sense Bariatric Device for treatment of morbid obesity
Liraglutide (Victoza®) for treatment of obesity
Lorcaserin (Lorgess®) for treatment of obesity
Maestro vagus nerve block system for treatment of morbid obesity
Methionine aminopeptidase 2 inhibitor (ZGN-433) for treatment of obesity
Naltrexone and bupropion HCL (Contrave®) for treatment of obesity
Tesofensine for treatment of obesity
Potential High Impact Report: Obesity
Obesity – Potential High Impact
19 topics were in the system 9 topics met eligibility criteria for high impact
assessment and 6 – 8 sets of expert comments were provided
Experts thought 7 of the 9 had no potential for high impact at this time
Phentermine/topiramate (Qnexa®): HIGH end of the high impact range
EndoBarrier endoluminal sleeve for excess weight loss – LOW end of high impact range
Leads for new topics
Trials fail to meet endpoints
Developer cannot procure
funding
FDA issues a negative decision
Intervention doesn’t diffuse
Safety issues appear
Better alternative developed
New trial results
become available
Topics already in the
system
Intervention reappears with new developer
Formulations, delivery
routes and combinations
change
Arthritis
Cancer
Cardiovascular
Dementia
Depression
Developmental Delay
Diabetes
Functional Limitations
Infectious Diseases
Obesity
Peptic Ulcer
Pregnancy
Pulmonary
Substance Abuse
Cross-Cutting
0% 20% 40% 60% 80% 100%
50%
84%
28%
80%
57%
17%
83%
76%
62%
75%
30%
10%
8%
69%
20%
43%
67%
15%
25%
60%
67%
17%
18%
33%67%
33%
Development StoppedNegative FDA DecisionExpert CommentsLittle UptakeDiffused Past 2 YrNot Meeting HS Criteria
Reasons for Archiving by Priority Area (as % of Archived Topics)
Reasons for Archiving by Priority Condition as Percentage of Topics in that Priority Condition
Arthrit
is
Cance
r
Cardi
ovas
cula
r
Demen
tia
Depre
ssio
n
Devel
opm
enta
l Del
ay
Diabe
tes
Funct
iona
l Lim
itatio
ns
Infe
ctio
us D
iseas
es
Obesit
y
Peptic
Ulce
r
Pregn
ancy
Pulm
onar
y
Subst
ance
Abu
se
Cross
-Cut
ting
0%
10%
20%
30%
40%
50%
60%
Not Meeting HS Criteria
Diffused Past 2 Yr
Little Uptake
Expert Comments
Negative FDA Decision
Development Stopped
Horizon Scanning Challenges
Drinking from the fire hose: – large volume of leads and topics
Tracking developments on 1000 topics already in the system and updating across all outputs
Fast pace of change Difficulty finding innovations in care delivery Difficulty getting broader input, including from
patients and clinicians, given PWRA requirements
Horizon Scanning Team
AHRQ: Elise Berliner, COTR ECRI:
– Diane Robertson, Project Manager– Randy Hulshizer, Content Team Leader– Eileen Erinoff, Director, Information Center– Jennifer DeLurio, Leads Manager– Marna Sanders, and 11 more fabulous medical
librarians, a.k.a. lead finders– Brian Wilkinson, and Abigail Dean - Senior
Horizon Scanning Analysts– Vladimir Cadet, Mike Leshinski, Marcus Lynch -
Horizon Scanning Analysts– And many more helping hands!